Compare BGSI & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | VKTX |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | N/A | 2015 |
| Metric | BGSI | VKTX |
|---|---|---|
| Price | $169.38 | $35.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $87.07 |
| AVG Volume (30 Days) | 42.4K | ★ 3.5M |
| Earning Date | 11-12-2025 | 10-22-2025 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $3,101,279,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $292.50 | ★ N/A |
| Revenue Growth | ★ 1.42 | N/A |
| 52 Week Low | $136.81 | $18.92 |
| 52 Week High | $177.20 | $52.58 |
| Indicator | BGSI | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.47 |
| Support Level | N/A | $32.90 |
| Resistance Level | N/A | $36.68 |
| Average True Range (ATR) | 0.00 | 1.99 |
| MACD | 0.00 | -0.46 |
| Stochastic Oscillator | 0.00 | 31.50 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.